Trials / Completed
CompletedNCT05759195
Biomolecular Analysis for Predicting Response to Regorafenib
Tumor Biomolecular Analysis for Defining Predictive Factors for Response to Regorafenib in Recurrent Glioblastoma
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Biomolecular tumor analysis | NGS analysis, other molecular analyses on FFPE tumor tissue |
Timeline
- Start date
- 2021-01-07
- Primary completion
- 2024-09-30
- Completion
- 2024-12-31
- First posted
- 2023-03-08
- Last updated
- 2025-03-13
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT05759195. Inclusion in this directory is not an endorsement.